{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:55:12Z","timestamp":1787500512009,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Introduction<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>Community-acquired pneumonia (CAP) requiring intensive care unit (ICU) treatment commonly causes acute respiratory failure with high mortality. Kallistatin, an endogenous tissue kallikrein inhibitor, has been reported to be protective in various human diseases. The aim of this study was to assess the correlations of kallistatin with other biomarkers and to determine whether kallistatin levels have a prognostic value in severe CAP.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    Plasma samples and clinical data were prospectively collected from 54 patients with severe CAP requiring ICU admission. Seventeen healthy control subjects were included for comparison. Plasma kallistatin, kallikrein, and other biomarkers of inflammation (tumor necrosis factor-\u03b1 (TNF-\u03b1), interleukin (IL)-1\u03b2, IL-6, IL-8, C-reactive protein (CRP)), and anti-coagulation (protein C, anti-thrombin III) were measured on days 1 and 4 of ICU admission. Comparison between survivors (\n                    <jats:italic>n<\/jats:italic>\n                    = 41) and nonsurvivors (\n                    <jats:italic>n<\/jats:italic>\n                    = 13) was performed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    Plasma kallistatin was significantly consumed in severe CAP patients compared with healthy individuals. Lower day 1 kallistatin levels showed a strong trend toward increased mortality (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.018) and higher day 1 CURB-65 scores (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.004). Plasma kallistatin levels on day 1 of ICU admission were significantly decreased in patients who developed septic shock (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.017) and who had acute respiratory distress syndrome (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.044). In addition, kallistatin levels were positively correlated with anti-thrombin III and protein C and inversely correlated with IL-1\u03b2, IL-6, and CRP levels. In a multivariate logistic regression analysis, higher day 1 CURB-65 scores were independent predictors of mortality (odds ratio = 29.9;\n                    <jats:italic>P<\/jats:italic>\n                    = 0.009). Also, higher day 1 kallistatin levels were independently associated with a decreased risk of death (odds ratio, 0.1) with a nearly significant statistical difference (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.056). Furthermore, we found that a cutoff level of 6.5 \u03bcg\/ml of day 1 kallistatin determined by receiver operating characteristic curves could be used to distinguish between patients who survived in 60 days and those who did not.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>These results suggest that kallistatin may serve as a novel marker for severe CAP prognosis and may be involved in the pathogenesis of CAP through antiinflammatory and anticoagulation effects.<\/jats:p>\n                  <jats:p>\n                    See related letter by Katz\n                    <jats:italic>et al.,<\/jats:italic>\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ccforum.com\/content\/17\/2\/429\">http:\/\/ccforum.com\/content\/17\/2\/429<\/jats:ext-link>\n                  <\/jats:p>","DOI":"10.1186\/cc12507","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T12:14:20Z","timestamp":1360325660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Plasma kallistatin levels in patients with severe community-acquired pneumonia"],"prefix":"10.1186","volume":"17","author":[{"given":"Wei-Chieh","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiou-Ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiou-Feng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Shin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"key":"1673_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1378\/chest.07-1456","volume":"133","author":"MI Restrepo","year":"2008","unstructured":"Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A: A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.\n                           Chest 2008, 133: 610-617. 10.1378\/chest.07-1456","journal-title":"Chest"},{"key":"1673_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/thorax.58.5.377","volume":"58","author":"WS Lim","year":"2003","unstructured":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study.\n                           Thorax 2003, 58: 377-382. 10.1136\/thorax.58.5.377","journal-title":"Thorax"},{"key":"1673_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1136\/thx.2008.105312","volume":"64","author":"R Menendez","year":"2009","unstructured":"Menendez R, Martinez R, Reyes S, Mensa J, Filella X, Marcos MA, Martinez A, Esquinas C, Ramirez P, Torres A: Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia.\n                           Thorax 2009, 64: 587-591. 10.1136\/thx.2008.105312","journal-title":"Thorax"},{"key":"1673_CR4","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.annemergmed.2008.12.022","volume":"53","author":"JD Chalmers","year":"2009","unstructured":"Chalmers JD, Singanayagam A, Scally C, Hill AT: Admission D-dimer can identify low-risk patients with community-acquired pneumonia.\n                           Ann Emerg Med 2009, 53: 633-638. 10.1016\/j.annemergmed.2008.12.022","journal-title":"Ann Emerg Med"},{"key":"1673_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1183\/09031936.00054507","volume":"31","author":"S Kruger","year":"2008","unstructured":"Kruger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T: Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes.\n                           Eur Respir J 2008, 31: 349-355. 10.1183\/09031936.00054507","journal-title":"Eur Respir J"},{"key":"1673_CR6","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1186\/cc10087","volume":"15","author":"F Bloos","year":"2011","unstructured":"Bloos F, Marshall JC, Dellinger RP, Vincent JL, Gutierrez G, Rivers E, Balk RA, Laterre PF, Angus DC, Reinhart K, Brunkhorst FM: Multinational, observational study of procalcitonin in ICU patients with pneumonia requiring mechanical ventilation: a multicenter observational study.\n                           Crit Care 2011, 15: R88. 10.1186\/cc10087","journal-title":"Crit Care"},{"key":"1673_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.annemergmed.2008.01.003","volume":"52","author":"DT Huang","year":"2008","unstructured":"Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, Angus DC: Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia.\n                           Ann Emerg Med 2008, 52: 48-58. e42 10.1016\/j.annemergmed.2008.01.003","journal-title":"Ann Emerg Med"},{"key":"1673_CR8","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jcrc.2010.10.007","volume":"26","author":"JH Lee","year":"2011","unstructured":"Lee JH, Kim J, Kim K, Jo YH, Rhee J, Kim TY, Na SH, Hwang SS: Albumin and C-reactive protein have prognostic significance in patients with community-acquired pneumonia.\n                           J Crit Care 2011, 26: 287-294. 10.1016\/j.jcrc.2010.10.007","journal-title":"J Crit Care"},{"key":"1673_CR9","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/cc11291","volume":"16","author":"LM Coelho","year":"2012","unstructured":"Coelho LM, Salluh JI, Soares M, Bozza FA, Verdeal JC, Castro-Faria-Neto HC, Lapa ESJR, Bozza PT, Povoa P: Patterns of c-reactive protein RATIO response in severe community-acquired pneumonia: a cohort study.\n                           Crit Care 2012, 16: R53. 10.1186\/cc11291","journal-title":"Crit Care"},{"key":"1673_CR10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/S0022-2143(96)90152-3","volume":"127","author":"J Chao","year":"1996","unstructured":"Chao J, Schmaier A, Chen LM, Yang Z, Chao L: Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease.\n                           J Lab Clin Med 1996, 127: 612-620. 10.1016\/S0022-2143(96)90152-3","journal-title":"J Lab Clin Med"},{"key":"1673_CR11","doi-asserted-by":"crossref","first-page":"25873","DOI":"10.1016\/S0021-9258(18)35690-4","volume":"267","author":"GX Zhou","year":"1992","unstructured":"Zhou GX, Chao L, Chao J: Kallistatin: a novel human tissue kallikrein inhibitor: purification, characterization, and reactive center sequence.\n                           J Biol Chem 1992, 267: 25873-25880.","journal-title":"J Biol Chem"},{"key":"1673_CR12","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1182\/blood-2002-01-0185","volume":"100","author":"RQ Miao","year":"2002","unstructured":"Miao RQ, Agata J, Chao L, Chao J: Kallistatin is a new inhibitor of angiogenesis and tumor growth.\n                           Blood 2002, 100: 3245-3252. 10.1182\/blood-2002-01-0185","journal-title":"Blood"},{"key":"1673_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1089\/hum.2006.17.1201","volume":"17","author":"J Chao","year":"2006","unstructured":"Chao J, Yin H, Yao YY, Shen B, Smith RS Jr, Chao L: Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation.\n                           Hum Gene Ther 2006, 17: 1201-1213. 10.1089\/hum.2006.17.1201","journal-title":"Hum Gene Ther"},{"key":"1673_CR14","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1161\/HYPERTENSIONAHA.107.108514","volume":"51","author":"B Shen","year":"2008","unstructured":"Shen B, Hagiwara M, Yao YY, Chao L, Chao J: Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress.\n                           Hypertension 2008, 51: 1358-1365. 10.1161\/HYPERTENSIONAHA.107.108514","journal-title":"Hypertension"},{"key":"1673_CR15","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/S0024-3205(97)00094-5","volume":"60","author":"LM Chen","year":"1997","unstructured":"Chen LM, Chao L, Chao J: Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock.\n                           Life Sci 1997, 60: 1431-1435. 10.1016\/S0024-3205(97)00094-5","journal-title":"Life Sci"},{"key":"1673_CR16","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/art.20991","volume":"52","author":"CR Wang","year":"2005","unstructured":"Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L, Chao J: Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation.\n                           Arthritis Rheum 2005, 52: 1319-1324. 10.1002\/art.20991","journal-title":"Arthritis Rheum"},{"key":"1673_CR17","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1089\/hum.2008.096","volume":"20","author":"JL Hsieh","year":"2009","unstructured":"Hsieh JL, Shen PC, Shiau AL, Jou IM, Lee CH, Teo ML, Wang CR, Chao J, Chao L, Wu CL: Adenovirus-mediated kallistatin gene transfer ameliorates disease progression in a rat model of osteoarthritis induced by anterior cruciate ligament transection.\n                           Hum Gene Ther 2009, 20: 147-158. 10.1089\/hum.2008.096","journal-title":"Hum Gene Ther"},{"key":"1673_CR18","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/labinvest.2008.85","volume":"88","author":"L Gao","year":"2008","unstructured":"Gao L, Yin HS, Smith RJ, Chao L, Chao J: Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction.\n                           Lab Invest 2008, 88: 1157-1166. 10.1038\/labinvest.2008.85","journal-title":"Lab Invest"},{"key":"1673_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3748\/wjg.v17.i1.111","volume":"17","author":"Y Diao","year":"2011","unstructured":"Diao Y, Zhao XF, Lin JS, Wang QZ, Xu RA: Protection of the liver against CCl4-induced injury by intramuscular electrotransfer of a kallistatin-encoding plasmid.\n                           World J Gastroenterol 2011, 17: 111-117. 10.3748\/wjg.v17.i1.111","journal-title":"World J Gastroenterol"},{"key":"1673_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1177\/002215549904700210","volume":"47","author":"WC Wolf","year":"1999","unstructured":"Wolf WC, Harley RA, Sluce D, Chao L, Chao J: Localization and expression of tissue kallikrein and kallistatin in human blood vessels.\n                           J Histochem Cytochem 1999, 47: 221-228. 10.1177\/002215549904700210","journal-title":"J Histochem Cytochem"},{"key":"1673_CR21","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","volume":"163","author":"MS Niederman","year":"2001","unstructured":"Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL, American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention.\n                           Am J Respir Crit Care Med 2001, 163: 1730-1754. 10.1164\/ajrccm.163.7.at1010","journal-title":"Am J Respir Crit Care Med"},{"key":"1673_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1097\/00003246-198510000-00009","volume":"13","author":"WA Knaus","year":"1985","unstructured":"Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system.\n                           Crit Care Med 1985, 13: 818-829. 10.1097\/00003246-198510000-00009","journal-title":"Crit Care Med"},{"key":"1673_CR23","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/BF01709751","volume":"22","author":"JL Vincent","year":"1996","unstructured":"Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.\n                           Intensive Care Med 1996, 22: 707-710. 10.1007\/BF01709751","journal-title":"Intensive Care Med"},{"key":"1673_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2119\/molmed.2009.00091","volume":"15","author":"EB Milbrandt","year":"2009","unstructured":"Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, Carter M, Yealy DM, Kellum JA: Prevalence and significance of coagulation abnormalities in community-acquired pneumonia.\n                           Mol Med 2009, 15: 438-445.","journal-title":"Mol Med"},{"key":"1673_CR25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/j.1440-1843.2010.01773.x","volume":"15","author":"DI Agapakis","year":"2010","unstructured":"Agapakis DI, Tsantilas D, Psarris P, Massa EV, Kotsaftis P, Tziomalos K, Hatzitolios AI: Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia.\n                           Respirology 2010, 15: 796-803. 10.1111\/j.1440-1843.2010.01773.x","journal-title":"Respirology"},{"key":"1673_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00109-009-0564-y","volume":"88","author":"S Oehmcke","year":"2010","unstructured":"Oehmcke S, Herwald H: Contact system activation in severe infectious diseases.\n                           J Mol Med (Berl) 2010, 88: 121-126. 10.1007\/s00109-009-0564-y","journal-title":"J Mol Med (Berl)"},{"key":"1673_CR27","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/thx.2006.067371","volume":"62","author":"G Barlow","year":"2007","unstructured":"Barlow G, Nathwani D, Davey P: The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia.\n                           Thorax 2007, 62: 253-259. 10.1136\/thx.2006.067371","journal-title":"Thorax"},{"key":"1673_CR28","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1097\/CCM.0b013e3182257445","volume":"39","author":"P Ramirez","year":"2011","unstructured":"Ramirez P, Ferrer M, Marti V, Reyes S, Martinez R, Menendez R, Ewig S, Torres A: Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia.\n                           Crit Care Med 2011, 39: 2211-2217. 10.1097\/CCM.0b013e3182257445","journal-title":"Crit Care Med"},{"key":"1673_CR29","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/01.CCM.0000153520.31562.48","volume":"33","author":"JF Dhainaut","year":"2005","unstructured":"Dhainaut JF, Shorr AF, Macias WL, Kollef MJ, Levi M, Reinhart K, Nelson DR: Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure.\n                           Crit Care Med 2005, 33: 341-348. 10.1097\/01.CCM.0000153520.31562.48","journal-title":"Crit Care Med"},{"key":"1673_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/00006676-199911000-00002","volume":"19","author":"M Blackberg","year":"1999","unstructured":"Blackberg M, Berling R, Ohlsson K: Tissue kallikrein in severe acute pancreatitis in patients treated with high-dose intraperitoneal aprotinin.\n                           Pancreas 1999, 19: 325-334. 10.1097\/00006676-199911000-00002","journal-title":"Pancreas"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/cc12507\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/cc12507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:56:32Z","timestamp":1728291392000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/cc12507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,2]]}},"alternative-id":["1673"],"URL":"https:\/\/doi.org\/10.1186\/cc12507","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]},"assertion":[{"value":"17 October 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R27"}}